Quantcast

Latest Santaris Pharma A/S Stories

2014-04-15 08:28:24

DUBLIN, Apr. 15, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6zn3pr/global_microrna ) has announced the addition of the "Global MicroRNA Market Report" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The analysts forecast the Global MicroRNA market to grow at a CAGR of 17.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in microRNA research funding....

2014-03-18 08:30:09

LONDON, March 18, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Global miRNA Market Outlook to 2018 The recent discovery of miRNA and its wide applicability have sparked off a lot of interest among researchers as well as commercial players. Owing to the same, there are numerous clinical trials being organized all over the world in order to assess the potential of miRNA in diverse fields such as Cancer, Asthma, Heart disorders, Diabetes, Hepatitis...

2014-01-10 08:23:28

HOERSHOLM, Denmark and SAN DIEGO, Jan. 10, 2014 /PRNewswire/ -- Santaris Pharma A/S has announced today that they have signed an agreement with GlaxoSmithKline (GSK), whereby, pursuant to an option right, GSK gains access to Santaris' Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines. Under the terms of the agreement, GSK can obtain rights to utilize Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform to research, develop and commercialize...

2014-01-09 08:27:30

HOERSHOLM, Denmark and SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Santaris Pharma A/S, a privately held biopharmaceutical company, announced today that they have signed a worldwide strategic alliance with Roche to discover and develop novel RNA targeted medicines using Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform. (Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO) Under the terms of the agreement, Santaris Pharma and Roche will collaborate on the...

2014-01-08 08:28:09

HOERSHOLM, Denmark, and SAN DIEGO, Jan. 8, 2014 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has hired J. Donald deBethizy, PhD as President and Chief Executive Officer (CEO), effective January 1, 2014. (Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO) Dr. deBethizy brings more than 20 years of experience in managing and financing life science...

2014-01-08 08:28:05

HOERSHOLM, Denmark, SAN DIEGO, and MUNICH, Jan. 8, 2014 /PRNewswire/ -- Santaris Pharma A/S and BetaIsarna Therapeutics GmbH announced today that they have signed an agreement whereby Isarna gains access to Santaris' Locked Nucleic Acid (LNA) technology to further develop its next generation oligonucleotide product candidates. Under the terms of the agreement, Isarna obtains rights to utilize Santaris Pharma's proprietary LNA Drug Platform to discover, develop and commercialize...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related